InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Reaches Agreement with ATERA SAS to Aid INM-750 Research in Pre-Clinical Tests
- InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020
- ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750
- INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://nnw.fm/5t7cL). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool, a biosynthesis manufacturing process, and drug development programs.
Vancouver-based InMed’s lead compound is INM-750, a proprietary topical cannabinoid product candidate aimed at treating skin disease epidermolysis bullosa (EB). EB is a skin disease which retards wound healing and can cause pain, itching, and inflammation. INM-750 may reverse the disease, for which there are currently no approved therapies. In its corporate presentation, InMed said that it sees a potential global market of $1 billion for INM-750, if approved.
ATERA SAS, as part of the agreement, will develop 3D human skin models that will assist InMed in assessing INM-750’s effectiveness in treating EB in vitro ahead of upcoming clinical trials estimated by InMed to take place in 2018, 2019 and 2020. ATERA SAS will produce 3D skin models in a controlled environment, creating a unique tool for drug development screening. ATERA SAS is expected to develop the 3D models from EB patient biopsies in order to help InMed assess INM-750.
ATERA SAS is a tissue engineering company tasked in this agreement with developing advanced human tissue models to assist InMed in analyzing pre-trial tests. The French company will also investigate INM-750 at the ultra-structural cellular and molecular levels. It will create 3D in vitro reconstructed human full thickness skin models of both normal and EB-derived skin cells.
At InMed, Dr. Ado Muhammed, MD, DPM and MFPM, is the chief medical officer. He previously served as associate medical director at GW Pharmaceuticals, where he was key in leading the company in the development and FDA approval of one of the first cannabis drugs. InMed is the only cannabis biotech company led by a former GW Pharmaceuticals executive.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020
- ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750
- INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://nnw.fm/5t7cL). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool, a biosynthesis manufacturing process, and drug development programs.
Vancouver-based InMed’s lead compound is INM-750, a proprietary topical cannabinoid product candidate aimed at treating skin disease epidermolysis bullosa (EB). EB is a skin disease which retards wound healing and can cause pain, itching, and inflammation. INM-750 may reverse the disease, for which there are currently no approved therapies. In its corporate presentation, InMed said that it sees a potential global market of $1 billion for INM-750, if approved.
ATERA SAS, as part of the agreement, will develop 3D human skin models that will assist InMed in assessing INM-750’s effectiveness in treating EB in vitro ahead of upcoming clinical trials estimated by InMed to take place in 2018, 2019 and 2020. ATERA SAS will produce 3D skin models in a controlled environment, creating a unique tool for drug development screening. ATERA SAS is expected to develop the 3D models from EB patient biopsies in order to help InMed assess INM-750.
ATERA SAS is a tissue engineering company tasked in this agreement with developing advanced human tissue models to assist InMed in analyzing pre-trial tests. The French company will also investigate INM-750 at the ultra-structural cellular and molecular levels. It will create 3D in vitro reconstructed human full thickness skin models of both normal and EB-derived skin cells.
At InMed, Dr. Ado Muhammed, MD, DPM and MFPM, is the chief medical officer. He previously served as associate medical director at GW Pharmaceuticals, where he was key in leading the company in the development and FDA approval of one of the first cannabis drugs. InMed is the only cannabis biotech company led by a former GW Pharmaceuticals executive.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
